Four serum neurofilament light chain tests show high accuracy in diagnosing ALS and predicting its progression, new research suggests.

The researchers repurposed the drug edaravone, an antioxidant used to treat amyotrophic lateral sclerosis (ALS), as a probe ...

Researchers have revealed a new scientific clue that could unlock the key cellular pathway leading to devastating neurodegenerative diseases like Alzheimer's disease and amyotrophic lateral sclerosis ...

A study indicates ALS Functional Rating Scale-Revised self-assessments using a smartphone app were as reliable as those done ...

Cognixion's Axon-R headset is a device designed to read brain activity using EEG as a direct input for controls. Using brain ...

Working with mouse cells, the researchers developed a highly efficient conversion method that can produce more than 10 ...

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a clinical trial nearly eight years ago, her symptoms have not gotten any worse.

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

In Nature Neuroscience, UConn School of Medicine researchers have revealed a new scientific clue that could unlock the key ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of ...

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead liver-targeting gene therapy into human trials. | As other gene editing programs ...